May 31, 2019 Conference


Update on Management of Macular Degeneration

Dr. Gregory Blaha, Lahey Medical Center (Presenter)

Treatment for wet AMD underwent a profound shift with the development of anti-vascular endothelial growth factor (anti-VEGF) medicines.  However, there has not been a new medicine approved for wet AMD since aflibercept in 2011 and there is still no treatment for dry AMD.  This talk will discuss current Phase 3 clinical trials for wet AMD including novel anti-VEGFs, drug delivery systems, anti-ang2 compounds, modified antibodies, and biosimilars.  Phase 3 trials for dry AMD will also be presented including complement inhibitors and visual cycle modulators.  In addition, there will be a brief summary of recently completed, unsuccessful Phase 3 trials for E10030 (Fovista) and Lampalizumab.